Ritlecitinib demonstrates long-term improvements in regrowth of scalp hair, eyebrows, and eyelashes at 24 months in adults and adolescents with alopecia areata (AA) and ≥ 25% scalp hair loss.

Researchers evaluated outcomes in 449 de novo adult and adolescent patients (mean age, 32.9 years) with AA and ≥ 25% scalp hair loss, enrolled in ALLEGRO-LT, an ongoing, open-label, phase 3 study evaluating long-term safety and efficacy of ritlecitinib, approved in 2023 for people with severe AA aged 12 years or older. Patients received ritlecitinib 200 mg daily for 4 weeks followed by 50 mg once daily (QD). The primary objective was to evaluate the safety and efficacy of ritlecitinib at 24 months; secondary endpoints included responses at month 24 based on the Severity of Alopecia Tool (SALT) score ≤ 20, SALT score ≤ 10, Patient Global Impression of Change (PGI-C) score improvements, and eyebrow and eyelash assessments.

"Long-term treatment with ritlecitinib 50 mg QD (with a 200-mg loading dose) was efficacious and well tolerated in adults and adolescents with AA [alopecia areata] and scalp hair loss ≥ 25%. Efficacy was observed in all subgroups based on baseline scalp hair loss, including patients with AT [alopecia totalis] and AU [alopecia universalis], with the highest treatment response observed in patients with 25%-50% scalp hair loss," the authors of the study wrote.

Source: MEDspace